ALOT vs PRLB

For growth investors, Proto Labs, Inc.

(PRLB) is the stronger pick with 6. 4% revenue growth year-over-year, versus 2. 2% for AstroNova, Inc. (ALOT). Proto Labs, Inc. (PRLB) offers the better valuation at 78. 3x trailing P/E (38. 0x forward), making it the more compelling value choice. Analysts rate AstroNova, Inc. (ALOT) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, AstroNova, Inc.

is actually cheaper at 22. 1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, AstroNova, Inc.

(ALOT) delivered a total return of -9. 9%, compared to -32. 0% for Proto Labs, Inc. (PRLB). Over 10 years, the gap is even starker: PRLB returned +15. 2% versus ALOT's +1. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AstroNova, Inc.

(ALOT) is the lower-risk stock at 0. 52β versus Proto Labs, Inc. 's 1. 84β — meaning PRLB is approximately 253% more volatile than ALOT relative to the S&P 500. On balance sheet safety, Proto Labs, Inc. (PRLB) carries a lower debt/equity ratio of 1% versus 64% for AstroNova, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Proto Labs, Inc.

(PRLB) is pulling ahead at 6. 4% versus 2. 2% for AstroNova, Inc. (ALOT). On earnings-per-share growth, the picture is similar: Proto Labs, Inc. grew EPS 33. 3% year-over-year, compared to -406. 3% for AstroNova, Inc.. Over a 3-year CAGR, ALOT leads at 8. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Proto Labs, Inc.

(PRLB) is the more profitable company, earning 4. 0% net margin versus -9. 6% for AstroNova, Inc. — meaning it keeps 4. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRLB leads at 4. 9% versus -5. 7% for ALOT. At the gross margin level — before operating expenses — PRLB leads at 44. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, AstroNova, Inc.

(ALOT) trades at 22. 1x forward P/E versus 38. 0x for Proto Labs, Inc. — 15. 9x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, AstroNova, Inc.

(ALOT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 52)). Proto Labs, Inc. (PRLB) carries a higher beta of 1. 84 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALOT: +1. 9%, PRLB: +15. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ALOT (Technology) and PRLB (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.